GlassScriptPhysician profile
Christopher M Mahr
NPI 1801880190
$4,746.98
in general payments reported to CMS, 2019-2025
38 companies · $35.42 in 2025
The $35.42 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $673 · 2021: $1,788 · 2022: $1,344 · 2023: $405 · 2024: $109 · 2025: $35.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $549.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $538.67 | 2021-2025 | |
| Novo Nordisk INC | $536.39 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $424.47 | 2019-2023 | Farxiga, Breztri |
| Amarin Pharma, INC. | $278.15 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $274.04 | 2021-2022 | |
| Glaxosmithkline, LLC. | $226.84 | 2019-2021 | |
| Pfizer INC. | $186.76 | 2019-2023 | |
| Amgen INC. | $180.06 | 2019-2023 | Otezla, Repatha |
| Exact Sciences Corporation | $164.43 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $161.83 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $146.88 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.09 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.58 | 2021-2023 | |
| Abbott Laboratories | $126.73 | 2021-2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $124.10 | 2019-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mahr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.